Oxford Biomedica: Lentivector Platform Expanding Into Haemophilia
Edison | Feb 16, 2018 07:51AM ET
Oxford BioMedica (LON:OXB) has announced a collaboration and licence agreement with Bioverativ to develop gene therapy products for the treatment of haemophilia. Under the terms of the agreement OXB will receive a $5m upfront payment, plus milestone payments (potentially worth in excess of $100m) and royalties on net sales of any commercialised products. This agreement further validates the value partners see in OXB’s LentiVector expertise and manufacturing capabilities. OXB now has multiple partnered products in various stages of development. Clinical progression and potential commercialisation of these could lead to substantial milestone and royalty revenues over the coming years. We place our numbers under review.
Exact timelines of the development were not disclosed. However, we anticipate that Bioverativ (and soon-to-be parent company, Sanofi (PA:SASY)) will put significant resources into this partnership to accelerate its gene therapy candidates into the clinic and narrow the gap between its competitors, Spark Therapeutics’ and BioMarin’s haemophilia gene therapies (which have impressive albeit early clinical data packages). As such, OXB could be a rapid beneficiary of the aforementioned milestones and any manufacturing revenues if a clinical supply agreement is later completed.
To read the entire report Please click on the pdf File Below:
Oxford Biomedica: Lentivector Platform Expanding Into Haemophilia
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.